Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed guidelines under your selection of "Location". The most recent guidelines are first.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 3. Skin Health Promotion: Health Promotion Interventions

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline provides recommendations regarding interventions aimed at the promotion of skin health. Specific topics discussed include the promotion of skin hygiene, promotion of comfort, preventing infections, protection from trauma, and protection from the environment.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 4. Management of Acute Radiation-Induced Skin Toxicities

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the clinical assessment and management of these patients. Outcomes of interest include improved care delivery and quality of life, enhanced treatment compliance, as well as minimized patient burden regarding dressings (i.e. cost, frequency/difficulty of dressing changes).

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 5. Management of Long-Term Effects

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the management of long term effects, and provides recommendations on 1 month post-treatment and late reactions to promote cleanliness, treat the wound, prevent infections, protect from trauma and the environment, promote skin health and maintain skin flexibility.

Provincial Consensus Recommendations for Adjuvant Systemic Therapy for Breast Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for patients with breast cancer. The guideline examines common approaches for the treatment of breast cancer with adjuvant systemic therapy. A specific topic discussed is the use of adjuvant therapy for HER2 positive breast cancer, with recommendations for both oncologists and pathologists.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the management of malignant melanoma. Topics of interest include acceptable time intervals from referral to surgical management, which patients should be candidates for sentinel lymph node biopsy, and acceptable surgical margins.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 2. Skin Assessment for Breast Cancer Patients Receiving Radiation

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adults with breast cancer. The guideline provides recommendations on the assessment and management of radiation-induced skin toxicities in these patients. Outcomes of interest include quality of life, treatment compliance, and minimized patient burden regarding dressings (e.g. cost, frequency, and difficulty of dressing changes).

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2018
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

Arsenic Trioxide for Acute Promyelocytic Leukemia

Year: 2014
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of acute promyelocytic leukemia with arsenic trioxide. The treatment is intended to be curative and to decrease regimen toxicity. Developers noted that acute promyelocytic leukemia is a rare subtype of acute leukemia (2.5 new cases in Manitoba per year in the last 10 years).

Third-Line Treatment of Stage IV or Advanced, Unresectable Colorectal Carcinoma with Cetuximab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with stage IV or advanced, unresectable colorectal carcinoma. The guideline examines the use of cetuximab as a third-line therapy once other therapies, including fluoropyrimidines, oxaliplatin, or irinotecan, had been tried or when patients are intolerant to other options. Outcomes of interest include progression-free and overall survival.

Consensus Recommendations for the Routine Use of Positron Emission Tomography (PET) Scan Imaging for Lymphoma in Manitoba

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with lymphoma, including small lymphocytic leukemia (SLL)/chronic lymphocytic leukemia (CLL), Waldenstroms, marginal zone lymphoma, and cutaneous lymphoma. The guideline examine the use of PET/CT, primarily for staging and response assessment. Outcomes of interest include survival, quality of life, and appropriate use.